© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Immunotherapy
Questioning When to Start Immunotherapy for Patients With Oncogenic Drivers
May 21, 2020
Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
BMI May Stratify Clinical Trials to Measure Survival With Immunotherapy in NSCLC
May 18, 2020
A study found correlation between body mass index in patients with non–small cell lung cancer treated with atezolizumab and improved survival outcomes.
Exploring Biomarkers for Immunotherapy Treatment in Lung Cancer
May 13, 2020
Jamie E. Chaft, MD, discusses biomarkers used to identify patients with lung cancer who would benefit from immunotherapy and the possibility for future biomarkers in this setting.
Doctors Debate: Should Immunotherapy Be Given Before or After Surgical Resection in Locally Advanced NSCLC?
April 22, 2020
“We don’t have a good understanding of why some patients have a robust response to immunotherapy and others do not. That’s important, not only in terms of selecting patients but also in terms of the therapy approach. This is one reason why clinical trials are incredibly important.”
Discussing the Evolution of Immunotherapy in Lymphomas
April 21, 2020
Joshua Brody, MD, discusses how he sees the use of immunotherapy evolving in coming years.
Expert Addresses Role of CAR T-Cell Therapy in Solid Tumors
April 14, 2020
Prasad S. Adusumilli, MD, FACS, discusses where he sees chimeric antigen receptor T-cell therapy fitting into the treatment landscape for patients with solid tumors.
Compelling Sacituzumab Govitecan Data in mTNBC Add to FDA Approval Hopes
April 07, 2020
Treatment with sacituzumab govitecan resulted in “compelling evidence of efficacy” in patients with metastatic triple-negative breast cancer, leading to an early halt of the phase III ASCENT study, announced Immunomedics in a press release.
ZUMA-2 Update: KTE-X19 Induced Durable Remission in R/R Mantle Cell Lymphoma
April 03, 2020
Durable remissions were elicited with KTE-X19 in a majority of patients with relapsed or refractory mantle cell lymphoma, according to the updated results from the ZUMA-2 trial published in the New England Journal of Medicine. The treatment did, however, cause serious adverse events that were consistent with known toxicities of chimeric antigen receptor T-cell therapy.
CAR T Cells Push Forward in Solid Tumors Following Positive Results in Hematology
April 01, 2020
In an interview with Targeted Oncology, Prasad S. Adusumilli, MD, FACS, discussed the expansion of chimeric antigen receptor T-cell research in the solid tumor space and the challenges researchers will need to overcome in order to make this therapy effective for patients outside of the hematologic treatment landscape.
Immunotherapy Induces Responses in Subtypes of Sarcomas
March 28, 2020
Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.